Pharma BD Deal Intelligence
Abbott's $6.6B Solvay Pharmaceuticals buy was a split decision: Creon became a durable double-digit-growth pancreatic enzyme franchise with ~80% share, but flagship AndroGel collapsed after 2015 generic entry and FDA cardiovascular warnings, plus drew a $448M antitrust judgment—netting a middling outcome relative to the price paid.
A patchwork deal: Creon became a durable double-digit grower, but AndroGel collapsed under generic entry, FDA safety warnings, and a $448M antitrust judgment — net a middling-to-poor outcome for the price paid.
Full analysis, sources & comparables →Credit Suisse's Catherine Arnold called the deal underwhelming — TriCor patents expire in two years and Solvay 'does not add long-term growth or reduce…
Abbott closed the acquisition February 16, 2010 for €4.5B cash plus up to €300M in milestones — adding ~$2.9B in 2010 sales (majority ex-US) and a…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott Laboratories acquired Solvay Pharmaceuticals for EUR 5.2B (~$6.6B) plus up to ~$440M in milestones, adding fenofibrate (TriCor/Trilipix), a vaccines business, and emerging-markets presence; closed February 2010.
A patchwork deal: Creon became a durable double-digit grower, but AndroGel collapsed under generic entry, FDA safety warnings, and a $448M antitrust judgment — net a middling-to-poor outcome for the price paid.
Assessment window: 15yr post-close.
$3.0B Solvay pharma annual sales added to Abbott (~$3B)
Dyslipidemia spans elevated LDL cholesterol, low HDL, and elevated triglycerides — major modifiable cardiovascular-risk factors. Statins are first-line for LDL reduction; fibrates (PPAR-alpha agonists) like fenofibrate target triglycerides and raise HDL, often used adjunctively in mixed dyslipidemia. The Solvay deal centered on the fenofibrate franchise (TriCor, Trilipix) plus a diversified portfolio in pancreatic enzyme replacement (Creon), testosterone replacement (AndroGel), and influenza vaccines.
By the September 2009 deal announcement, the US dyslipidemia market was dominated by statins — Pfizer's Lipitor (atorvastatin), AstraZeneca's Crestor (rosuvastatin), and generic simvastatin/pravastatin/lovastatin (post-2006 patent cliff). Fibrates carved out a smaller adjunctive niche; Solvay's TriCor (fenofibrate) and Trilipix (fenofibric acid, a delayed-release prodrug-free form designed to bridge the upcoming TriCor patent expiry) were the category leaders versus Antara, Lofibra, and Lipofen generic equivalents. Credit Suisse analyst Catherine Arnold flagged that fenofibrate patent expiries within two years meant 'Solvay does not add long-term growth or reduce Abbott's dependence on Humira' — a Negative analyst take. Morgan Stanley's David Lewis offered a Neutral framing: 'marginal diversification' but improved European and emerging-markets reach. Abbott also gained AndroGel (a top-three testosterone gel competing with Auxilium's Testim and Eli Lilly's Axiron), Creon (pancreatic enzyme replacement; competitors Zenpep and Pancreaze were ramping post-2010 FDA action), and a flu/seasonal vaccines business. Strategically the deal added ~$3B in non-US revenue but the lack of Humira-scale growth assets made it the weakest of Abbott's major 2000s acquisitions; the fenofibrate franchise lost exclusivity in 2012-2013 as analysts predicted.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Solvay Pharmaceuticals (Solvay Group) (this deal) | 2009 | $6.6B | 51 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2009 deals · Abbott Laboratories deals